Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 449

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group

Lee, Anne W.M., Lau, W.H., Tung, Stewart Y., Chua, Daniel T.T., Chappell, Rick, Xu, L., Siu, Lillian, Sze, W.M., Leung, T.W., Sham, Jonathan S.T., Ngan, Roger K.C., Law, Stephen C.K., Yau, T.K., Au, Joseph S.K., O'Sullivan, Brian, Pang, Ellie S.Y., O, S.K., Au, Gordon K.H., Lau, Joseph T.·2005·Journal of Clinical Oncology

Abstract

Purpose: This randomized study compared the results achieved by concurrent chemoradiotherapy (CRT) versus radiotherapy (RT) alone for nasopharyngeal carcinoma (NPC) with advanced nodal disease. Patients and Methods: Patients with nonkeratinizing/undifferentiated NPC staged T1-4N2-3M0 were randomized to CRT or RT. Both arms were treated with the same RT technique and dose fractionation. The CRT patients were given cisplatin 100 mg/m 2 on days 1, 22, and 43, followed by cisplatin 80 mg/m 2 and fluorouracil 1,000 mg/m 2/d for 96 hours starting on days 71, 99, and 127. Results: From 1999 to January 2004, 348 eligible patients were randomly assigned; the median follow-up was 2.3 years. The two arms were well-balanced in all prognostic factors and RT parameters. The CRT arm achieved significantly higher failure-free survival (72% v 62% at 3-year, P = .027), mostly as a result of an improvement in locoregional control (92% v 82%, P = .005). However, distant control did not improve significantly (76% v 73%, P = .47), and the overall survival rates were almost identical (78% v 78%, P = .97). In addition, the CRT arm had significantly more acute toxicities (84% v 53%, P < .001) and late toxicities (28% v 13% at 3-year, P = .024). Conclusion: Preliminary results confirmed that CRT could significantly improve tumor control, particularly at locoregional sites. However, there was significant increase in the risk of toxicities and no early gain in overall survival. Longer follow-up is needed to confirm the ultimate therapeutic ratio.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2004.00.7542

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 449

Metadata

Authors
Lee, A. W. M., Lau, W. H., Tung, S. Y., Chua, D. T. T., Chappell, R., Xu, L., Siu, L., Sze, W. M., Leung, T. W., Sham, J. S. T., Ngan, R. K. C., Law, S. C. K., Yau, T. K., Au, J. S. K., O'Sullivan, B., Pang, E. S. Y., O, S. K., Au, G. K. H., & Lau, J. T.
Venue
Journal of Clinical Oncology
Published
2005-10-01
Volume
23
Issue
28
Pages
6966-6975
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2161612574
Cited by
449
References
15
FWCI
19.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. https://app.cochat.ai/papers/10.1200/jco.2004.00.7542
The paper
Lee, A. W. M., Lau, W. H., Tung, S. Y., Chua, D. T. T., Chappell, R., Xu, L., Siu, L., Sze, W. M., Leung, T. W., Sham, J. S. T., Ngan, R. K. C., Law, S. C. K., Yau, T. K., Au, J. S. K., O'Sullivan, B., Pang, E. S. Y., O, S. K., Au, G. K. H., & Lau, J. T. (2005). Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.00.7542

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.